Chargement en cours...
Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis
Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown promising results in a small group of systemic lupus erythematosus (SLE) patients treated for lupus nephritis (LN). However, such observations were not confirmed in the double-blind LUNAR study. Accordingly, the factors associated with the...
Enregistré dans:
| Publié dans: | Clin Kidney J |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5094396/ https://ncbi.nlm.nih.gov/pubmed/27818754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfs162 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|